BioCentury
ARTICLE | Financial News

Ascendis, Aimmune price upsized follow-ons

February 22, 2018 8:03 PM UTC

Endocrinology company Ascendis Pharma A/S (NASDAQ:ASND) and allergy play Aimmune Therapeutics Inc. (NASDAQ:AIMT) raised a total of $401 million late Wednesday in bumped-up follow-ons.

Ascendis raised $225 million through the sale of 3.9 million ADSs at $57 in an offering underwritten by J.P. Morgan, BofA Merrill Lynch, Credit Suisse, Wells Fargo, Stifel and Wedbush PacGrow. The price was a 3% discount to Ascendis' closing price of $59 on Tuesday, when the company proposed after market hours to raise $150 million. Ascendis slipped $1 to $58 on Wednesday, then added $1.43 to $59.43 on Thursday...